Sam­sung Bioepis switch­es gears, moves from knock­offs to new drugs with fast-chang­ing Take­da

Sam­sung Bioepis knows how to make a great copy of a bi­o­log­ic. Now the com­pa­ny wants to start cre­at­ing them from scratch.

The biosim­i­lars mak­er, al­lied with Bio­gen on de­vel­op­ing gener­ic ver­sions of brand­ed bi­o­log­ics, to­day un­veiled a new al­liance with Japan’s ag­gres­sive Take­da on co-de­vel­op­ing a pipeline of new drugs.

First up is a Take­da drug, TAK-671, for acute pan­cre­ati­tis.

Christo­pher Han­sung Ko, the CEO of Sam­sung Bioepis, put it this way:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER